摘要
目的:研究探讨惠迪粒对溃疡性结肠炎患者的治疗效果及血清白介素(IL-6)和肿瘤坏死因子(TNF-α)的影响。方法:随机选取在本院确诊为溃疡性结肠炎的患者150例,随机平均分为两组,研究组(75例)采用惠迪粒(美沙拉嗪缓释颗粒)治疗;对照组(75例)采用柳氮磺胺吡啶(SASP)治疗,观察比较两组的临床效果及治疗前后血清IL-6、TNF-α的变化情况。结果:研究组治疗效果明显优于对照组,差异有统计学意义(P<0.05);两组患者治疗后的IL-6、TNF-α水平较治疗前明显降低(P<0.05);并且研究组患者IL-6、TNF-α水平降低程度比对照组更加明显,差异有统计学意义(P<0.05)。结论:惠迪粒治疗溃疡性结肠炎具有良好临床疗效,考虑可能是通过降低血清中IL-6、TNF-α水平而起作用的,其具体机制尚有待进一步研究完善。
Objective： To study the influence of the Huidi grain＇s effect on the treatment of patients with ulcerative colitis and serum interleukiu （ IL-6 ）, tumor necrosis factor （ TNF- α ） . Method： We randomly selected 150 patients in our hospital diagnosed with ulcerative colitis and randomly divided into two groups, the study group （ 75 cases ） adopt the Huidi grain （ mesalazine slow-release granules ） treatment; the control group （ 75 cases ） adopt sulfasalazine （ SASP ） therapy clinical , observe and compare the two sets of clinical effect and the changes of serum IL-6, TNF- α of before and after treatment. Result： The therapeutic effect of the study group was significantly better than the control group, the difference was statistically significant （ P〈0.05 ） ; After treatment, IL-6, TNF- α levels are reduced than before significantly （ P〈0.05 ） ; Study group patients with IL-6, TNF- α levels decreased more significantly than the control group, the difference was statistically significant （ P〈0.05 ） . Conclusion： The Huidi grain treatment of ulcerative colitis has good clinical efficacy, considering the possibility of works by lowering the serum level of IL-6, TNF-α, the exact mechanism remains to be further study and improve.
出处
《中国医学创新》
CAS
2013年第11期17-18,共2页
Medical Innovation of China
